National Research Corporation Common Stock (Delaware)
National Research Corporation Common Stock (Delaware) (NRC): 10 pipeline candidates · 2 upcoming catalysts · ~2 mo cash runway · 75 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
1.7 months
D/E 8.97 · 0% dilution
Lead: Phase 1/Phase 2
10 candidates
2 upcoming, next in ~561d
1 buy · 0 sells (180d)
A transparent, data-derived signal for National Research Corporation Common Stock (Delaware)across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$405.5M
Cash
$2.5M
Quarterly Burn
$13.4M
Runway
1.7 mo
Revenue
$34.8M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (10 candidates)
| Drug | Phase |
|---|---|
| 15-0 h20 | — |
| aav9-glb1 | Phase 1/Phase 2 |
| amicar | Phase 2 |
| cysteamine | — |
| intrathecal resiniferatoxin | Phase 1 |
| label chg for erika model 9608 arterial blood line | — |
| mannac | Phase 2 |
| mk-7075 | Phase 2 |
| pth-ia | Phase 1/Phase 2 |
| sgt-53 | Early Phase 1 |
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
120
Total value held
$186.1M
| Holder | Shares | Value |
|---|---|---|
| kayne anderson rudnick investment management llc | 2,636,355 | $44.8M |
| vanguard capital management llc | 1,325,674 | $22.5M |
| morgan stanley | 1,001,880 | $17.0M |
| blackrock, inc. | 975,855 | $16.6M |
| dimensional fund advisors lp | 489,740 | $8.3M |
| geode capital management, llc | 393,847 | $6.7M |
| renaissance technologies llc | 340,784 | $5.8M |
| state street corp | 300,748 | $5.2M |
| hotchkis & wiley capital management llc | 286,840 | $4.9M |
| northern trust corp | 255,601 | $4.3M |
Showing top 10 of 120 institutional holders of National Research Corporation Common Stock (Delaware). Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in National Research Corporation Common Stock (Delaware)'s pipeline?
National Research Corporation Common Stock (Delaware) (NRC) has 10 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is National Research Corporation Common Stock (Delaware)'s next catalyst?
National Research Corporation Common Stock (Delaware)'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of" — expected December 31, 2027.
What is National Research Corporation Common Stock (Delaware)'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, National Research Corporation Common Stock (Delaware) has approximately 1.7 months of cash runway.
What is National Research Corporation Common Stock (Delaware)'s market capitalization?
National Research Corporation Common Stock (Delaware)'s market capitalization is approximately $405.5M.
Who is the CEO of National Research Corporation Common Stock (Delaware)?
Mr. Trent S. Green is the chief executive officer of National Research Corporation Common Stock (Delaware) (NRC).
Get the full picture on National Research Corporation Common Stock (Delaware)
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.